Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brain

Gene Therapy

Volumn 12, Issue 8, 2005, Pages 647-654

  Liu, R ^a,c   Martuza, R L ^a,b   Rabkin, S D ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Brain tumors; Herpes simplex virus; Osmotic disruption; Virotherapy

Indexed keywords

ARABINOSE; EVANS BLUE; GALACTOSE; HERPESVIRUS VECTOR; MANNITOL; ONCOLYTIC VIRUS; PHOSPHATE BUFFERED SALINE; PYRANOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CAROTID ARTERY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FEMALE; GENE DELETION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS G47DELTA VECTOR; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CAROTID ARTERIES; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRA-ARTERIAL; LIVER; LUNG; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSMOSIS; SIMPLEXVIRUS;

ANIMALIA; HERPES; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 17644407319     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302445     Document Type: Article

References (51)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
2. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
3. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
4. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene non-essential for growth in culture. Science 1990; 250: 1262-1266.
5. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
6. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396-6401.
7. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J 1996; 15: 4759-4766.
8. York IA et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 1994; 77: 525-535.
9. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy Study Cancer 1983; 52: 2349-2354.
10. Posner JB, Chernick NL. Intracranial metastases from systemic cancer. Adv Neurol 1987; 19: 579-592.
11. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474-1480.
12. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983; 23: 175-180.
13. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698-2705.
14. Crivellari D et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001; 12: 353-356.
15. Bendell JC et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-2977.
16. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177-2185.
17. Mahmoud-Ahmed AS et al. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002; 54: 810-817.
18. Lang FF, Sawaya R. Surgical treatment of metastatic brain tumors. Semin Surg Oncol 1998; 14: 53-63.
19. Lagerwaard FJ et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
20. De Boer AG, Breimer DD. The blood-brain barrier: clinical implications for drug delivery to the brain. J R Coll Physicians Lond 1994; 28: 502-506.
21. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002; 36: 555-558.
22. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000; 20: 217-230.
23. Black KL. Biochemical opening of the blood-brain barrier. Adv Drug Del Rev 1995; 15: 37-52.
24. Doolittle ND et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000; 88: 637-647.
25. Prados MD et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol 2003; 5: 96-103.
26. Kroll RA et al. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 1998; 43: 879-886; discussion 886-879.
27. Nilaver G et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA 1995; 92: 9829-9833.
28. Rainov NG et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther 1995; 6: 1543-1552.
29. Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980; 238: R421-R431.
30. Liu R, Rabkin SD. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J 2005, in press.
31. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200: 639-646.
32. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891-899.
33. Lu S, Ahn D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol 2003; 24: 937-941.
34. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004; 54: 131-140; discussion 141-132.
35. Green NK, Seymour LW. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther 2002; 9: 1036-1042.
36. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy 2003; 10: 983-990.
37. Fredericks WR, Rapoport SI. Reversible osmotic opening of the blood-brain barrier in mice. Stroke 1988; 19: 266-268.
38. Wiranowska M, Wilson TC, Bencze KS, Prockop LD. A mouse model for the study of blood-brain barrier permeability. J Neurosci Methods 1988; 26: 105-109.
39. Murakami H et al. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol 2000; 279: H1022-H1028.
40. Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy 2000; 7: 1648-1655.
41. Neuwelt EA, Pagel MA, Dix RD. Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 1991; 74: 475-479.
42. Rainov NG, Kramm CM. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr Gene Ther 2001; 1: 367-383.
43. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74: 3832-3841.
44. Wakimoto H et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275-282.
45. Ikeda K et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887.
46. Bergman I et al. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 2000; 49: 259-266.
47. Szalai AJ et al. The Arthus reaction in rodents: species-specific requirement of complement. J Immunol 2000; 164: 463-468.
48. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multi-mutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-4756.
49. Advani SJ et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59: 2055-2058.
50. Todo T et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588-595.
51. Cailleau R, Olive M, Crucigar QV. Long term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In vitro 1978; 14: 911-915.